ABsTRAcr Forty seven patients (82 % male) with pulmonary infection caused by Mycobacterium xenopi have been reviewed. Pre-existing lung disease was present in 35 (75 %). In 21 patients the disease was characterised by a subacute illness developing over a period of two to four months, while in another 20 patients there was a longer history of chronic respiratory problems often associated with slowly progressive changes evident from chest radiographs. Response to treatment was poor and unpredictable, and was not related to the results of in vitro sensitivity tests, pre-existing lung disease, or mode of onset of symptoms. Eleven patients (23 %) were cured with chemotherapy. The best drug regimen appeared to be rifampicin and isoniazid combined with either streptomycin or ethambutol. Another 12 (26%) showed favourable responses to drug treatment initially, but eventually relapsed. Four patients had progressive disease while receiving prolonged courses of chemotherapy. Resection was performed in five patients with resultant cure in four. Since the prognosis with drug treatment alone is so unpredictable it is suggested that resection might be part of first line treatment, and that it should usually be performed if patients fail to respond to initial chemotherapy or if they relapse.
Published reports have suggested that pulmonary infection with Mycobacterium xenopi responds to antituberculous chemotherapy and carries a relatively good prognosis for cure.'3 Much of the information on which these views are based, however, has been obtained from small series or case reports on individual patients. Moreover, with the exception of a recent paper by Smith and Citron,4 follow up periods have been either short or not documented.'-3 S-9 It has not therefore been possible to assess accurately the effect of chemotherapy or surgery on the long term prognosis of patients with this condition. We have studied 47 patients with M xenopi infection presenting over a 10 year period in an attempt to assess their response to treatment and prognosis for cure and to identify the forms of treatment most likely to lead to successful outcome.
Methods
The names of 90 patients whose sputa had yielded Address 
Results
Of the 47 patients reveiwed, 39 (82%) were male and the mean age of the group was 61-5 years (range 36-84). Pre-existing lung disease was present in 35 cases (75%), of which healed M tuberculosis infection accounted for 14, chronic bronchitis and emphysema 12, and bronchiectasis three; whilst three others had interstitial pulmonary fibrosis (asbestosis, chronic bird fancier's lung, and cryptogenic fibrosing alveolitis). One patient had coalworkers' pneumoconiosis and another intrinsic asthma, and another gave a past history of lobar pneumonia. Two at least nine months' chemotherapy. Most patients case. Both had unilateral disease radiographically had initially received rifampicin and isoniazid com-and active disease was present in both resected bined with either ethambutol or streptomycin specimens. The seventh patient who was retreated despite the in vitro sensitivity patterns, and all showed an initial satisfactory response but again improved. All 12 became sputum culture negative relapsed 17 months after the end of treatment. Curbut this was accompanied by radiographic improve-rently she remains stable while continuing on a third ment in only eight patients. Cavitation persisted in course of treatment, although she has a destroyed, all twelve. Despite these satisfactory initial cavitated, fibrosed right upper lobe. responses all relapsed at a later date. The results of Three of the five patients who were not retreated retreatment were generally poor. Six of the seven showed slowly progressive disease, one subsepatients receiving second courses of chemotherapy quently dying from his infection. Two others not developed progressive disease despite treatment retreated have remained clinically stable throughout with multiple drug regimens chosen according to the their prolonged follow up, although both have in vitro sensitivity. The affected lobes were resected extensively fibrosed and cavitated upper lobes with in two of these patients, with resultant cure in each occasional positive sputum cultures. (table 6) . Four had progressive dislated causes while receiving treatment. Of the ease while receiving prolonged courses of treatment remaining three, two showed initial improvement with multiple appropriate drug regimens derived while receiving treatment for six months and four from results of in vitro sensitivity tests. One patient months respectively but relapsed with progressive had early resection followed by nine months' disease within months of stopping chemotherapy. chemotherapy with resultant cure, and has remained The remaining patient has stable disease three years well for the seven years since operation. A second after treatment.
patient was eventually cured after resection but the A further four patients initially received less than other two died from their disease after the end of nine months' treatment, but were later treated for chemotherapy. The fifth patient is considered cured more prolonged periods, with variable responses but has been having treatment for five years so far. (table 5) . One patient had progressive disease during the 11 years following the initial treatment and PATIENTS WHO DID NOT HAVE CHEMOTHERAPY more recently has received a second course of Four patients (not tabulated) received no In our series 23 % of patients have not so far relapsed and fulfil our criteria for cure. Most of these patients had been treated with rifampicin and isoniazid combined with either streptomycin or ethambutol. There were no features which allowed separation of the patients who were to do well from those who had an unfavourable outcome; in particular, neither the mode of onset nor the presence or absence of pre-existing disease were useful as predictors of response. Possibly there was some impairment of immune response in those patients who had unfavourable responses to treatment, although we are not aware of any experimental evidence on this point. Impaired immunological responses may also be important in the pathogenesis of invasive disease as well as in the persistence of simple colonisation with the organism.
We were unable to determine an adequate period of treatment, but it was apparent that those patients who received chemotherapy for less than nine months did not do well. Furthermore, a failure to treat was always followed by progressive disease, which in one patient continued for 10 years.
Resection was performed because of failure to respond to chemotherapy or because of subsequent relapse in four patients, with resultant cure in all, the follow up ranging from three and a quarter to seven years. The fifth patient undergoing surgery died two weeks later from postoperative pneumonia. She had 382 deteriorated with untreated progressive disease during the three years preceding surgery and suffered from chronic bronchitis. Since the prognosis with drug treatment alone is so unpredictable in this condition there would seem to be a good argument for resection in some patients, particularly those who fail to respond initially to chemotherapy or who relapse. Earlier intervention while the disease remains limited is likely to carry a better chance of success. Even so, coexistent pulmonary disease or other conditions may often preclude operative management in these patients.
